新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 百时美施贵宝 » 百时美施贵宝与CytomX签署$12.4亿协议合作开发新颖的抗体疗法

百时美施贵宝与CytomX签署$12.4亿协议合作开发新颖的抗体疗法

来源:生物谷 2014-05-28 10:01

2014年5月27日讯 /生物谷BIOON/ --百时美施贵宝(BMS)和CytomX治疗公司5月27日联合宣布,双方已签署了一项全球性研究合作及授权协议,发现、开发和商业化利用CytomX专有的Probody抗体平台开发的靶向数个免疫肿瘤学靶标的新颖疗法。

Probody是一类完全重组的单克隆抗体,其抗原结合位点利用专利性的抗体掩蔽技术进行封闭,在健康组织中保持惰性,而在肿瘤微环境中能被肿瘤特异的蛋白酶切割从而被选择性激活,暴露出抗原结合位点。Probody聚焦于治疗性抗体对肿瘤的活性,同时对健康组织无害。Probody独特的选择性,扩展了已验证及新颖靶标的治疗窗口,有望创造更安全有效的新一类疗法。

根据协议条款,CytomX授予百时美施贵宝Probodies用于4个肿瘤学靶标的全球独家开发和商业化权利,包括CTLA-4,这是一种已临床证实的免疫抑制检查点受体。

百时美施贵宝将支付5000万美元预付款。若4个靶标均达到开发、监管、销售里程碑,针CytomX将获得高达近12亿美元的里程碑款项,以及产品销售的特许权使用费。

关于Probody作用原理,详见CytomX公司主页动画:How Probodies Work

英文原文:Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets

NEW YORK & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc. today announced the companies have signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody™ Platform.

Probodies are monoclonal antibodies that are selectively activated within the cancer microenvironment, focusing the activity of therapeutic antibodies to tumors and sparing healthy tissue. The unique selectivity of Probodies expands the therapeutic window for both validated and novel targets, and has the potential to create multiple new classes of safer and more effective therapies.

“Immuno-oncology offers a tremendous opportunity to change how cancer is treated, and Bristol-Myers Squibb is committed to advancing our immuno-oncology drug research and development for patients living with the disease,” said Francis Cuss, MB BChir, FRCP, executive vice president and chief scientific officer, Bristol-Myers Squibb. “The Probody Platform has the potential to broaden discovery of innovative therapies, and the collaboration with CytomX reflects our continued leadership in immuno-oncology.”

Under the terms of the agreement, CytomX will grant Bristol-Myers Squibb exclusive worldwide rights to develop and commercialize Probodies for up to four oncology targets including CTLA-4, a clinically validated immune inhibitory checkpoint receptor. Bristol-Myers Squibb will have certain additional rights to substitute up to two collaboration targets. Bristol-Myers Squibb will make an upfront payment of $50 million to CytomX and provide research funding over the course of the research term. CytomX will also be eligible to receive additional preclinical payments and up to $298 million in future development, regulatory and sales milestone payments for each collaboration target, as well as tiered mid-single-digit rising to low-double-digit royalty payments on net sales of each product commercialized by Bristol-Myers Squibb. Closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

“We are thrilled to announce our first cancer immunotherapy collaboration with an unequivocal leader in this field,” said Sean McCarthy, D.Phil., chief executive officer of CytomX. “This strategic alliance with Bristol-Myers Squibb demonstrates that our innovative Probody Platform has the potential to enable novel therapies in this transformational area of cancer research and development. This collaboration, together with our recently announced partnerships in the Probody Drug Conjugate space, illustrate the breadth of Probody technology and how we aim to make a difference in the lives of patients. We look forward to collaborating with Bristol-Myers Squibb to advance highly differentiated Probody therapeutics into development.”

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库